This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
FCPA Blog – Revisiting EpiPen: Steep incentive thresholds are corporate disasters waiting to happen
February 13, 2017
Marc Hodak, partner at Farient Advisors, explains how steep incentive thresholds were behind the Epipen scandal and how companies can learn from Mylan’s mistake.
Read More© 2025 Farient Advisors LLC. | Privacy Policy | Site by: Treacle Media